Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

S. Weber, Jeffrey; Mandalà, Mario; Del Vecchio, Michele; Gogas, Helen; Arance, Ana; Lance Cowey, C.; Dalle, Stéphane; Schenker, Michael; Chiarion‐Sileni, Vanna; Márquez‐Rodas, Iván; Grob, Jean-Jacques; O. Butler, Marcus; R. Middleton, Mark; Maio, Michele; Atkinson, Victoria; Queirolo, Paola; González, René; R. Kudchadkar, Ragini; Smylie, Michael; Meyer, Nicolás; Mortier, Laurent; B. Atkins, Michael; V. Long, Georgina; Bhatia, Shailender; Lebbé, Célèste; Rutkowski, Piotr; Yokota, Kenji; Yamazaki, Naoya; M. Kim, Tae; de Pril, Veerle; Sabater, Javier; Qureshi, Anila; Larkin, James; A. Ascierto, Paolo

doi:10.1056/nejmoa1709030

Public

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Published in New England Journal of Medicine • Sep 10, 2017

Authors:

Jeffrey S. Weber

Mario Mandalà

Michele Del Vecchio

Abstract

BACKGROUND: Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence-free and overall survival rates that were higher t...

Subject

Ipilimumab

Nivolumab

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!